Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netarsudil for Prevention of Corticosteroid-induced IOP Elevation
NCT03248037Phase 3Completed
- Sponsor
- Cornea Research Foundation of America
- Start
- Sep 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ocular hypertension comparing Netarsudil with Placebo (2 arms). Primary endpoint: Intraocular Pressure Elevation at 9 months. Started Sep 2017; status: completed.
02
Drugs
netarsudil
03
Conditions
ocular hypertension
Beyond the preview
Go deeper on NCT03248037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03248037.